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The study of the intersection of immunology and metabolism is a growing field fueled by the increased prev-
alence of obesity-associated pathologies. Importantly, the capacity of the innate immune system to sense
metabolic stress induced by nutritional surplus has been linked with the progression of obesity, insulin resis-
tance, type 2 diabetesmellitus, nonalcoholic fatty liver disease, and atherosclerosis. Moreover, it is clear that
the innate immune system regulates the composition of the intestinal microbiota, which impacts multiple
host metabolic processes. Here we review recent studies in this emerging field with an emphasis on how
innate immune receptors determine metabolic disease progression.Introduction
Obesity is a growing epidemic worldwide. Nearly 35% (1.4 billion
people) of the world’s adult population was overweight and 11%
(500 million people) was obese in 2008, and at least 2.8 million
adults die as a result of being overweight or obese each year.
The prevalence of obesity has been rising tremendously over
the last 30 years; moreover, the number of overweight children
under the age of 5 was estimated to be over 42 million in 2010
(World Health Organization, 2013). Obesity is closely associated
with multiple metabolic abnormalities such as insulin resistance,
hyperlipidemia, hepatic steatosis, and hypertension. The devel-
opment of obesity and related metabolic disorders increases
the risk for type 2 diabetes mellitus (T2DM), nonalcoholic
fatty liver disease (NAFLD), and cardiovascular disease. These
pathologies are a tremendous burden for individuals and
societies, as they dramatically worsen the quality of life, and
their treatment requires significant financial resources from
health care systems (Gregor and Hotamisligil, 2011; Samuel
and Shulman, 2012).
Importantly, obesity is associated with a chronic, low-grade
inflammation termed metabolic inflammation (Gregor and Hota-
misligil, 2011), which is now considered a focal point in the initia-
tionandprogressionof insulin resistance, T2DM,atherosclerosis,
andNAFLD.Thus, understanding themechanismof inflammation
in thepathogenesis of thesediseases is increasingly important for
the development of future therapeutic approaches.
In mammals, multiple recognition systems have coevolved
to sense exogenous or endogenous pathogen-associated
molecular patterns (PAMPs) and danger-associated molecular
patterns (DAMPs), and thereby mediate immune response to-
ward invading microbes and tissue damage. Toll-like receptors
(TLRs) predominantly recognize microbe- or host-derived insults
in the extracellular or endosomal compartments, whereas NOD-
like receptors (NLRs) sense invading intracellular pathogens and
intracellular perturbations associated with stress or damage.
There are 10 human TLRs and 12 mouse TLRs. Among them,
TLR2 forms heterodimers with TLR1 or TLR6 to sense lipopepti-
des, peptidoglycan (PGN), and lipoteichoic acid from gram-pos-itive bacteria; TLR4 recognizes lipopolysaccharide (LPS) of
gram-negative bacterial cell walls; TLR5 binds to flagellin from
flagellated bacteria; and TLR9 detects unmethylated CpGmotifs
present in bacteria-derived DNA (Kawai and Akira, 2010). Among
the 22 NLR genes that have been identified in human so far,
NOD1 and NOD2 sense bacterial PGN. Specifically, NOD1 rec-
ognizes meso-diaminopimelic acid found predominantly in
gram-negative bacteria, whereas NOD2 detects muramyl dipep-
tide (MDP) present in all bacteria. In addition, NLRP1b recognizes
anthrax lethal toxin, NLRC4 responds to bacterial flagellin and
the apparatus of type III secretion systems, the best-character-
ized NLRP3 has been identified to sense a number of virus and
intracellular bacteria as well as certain fungi, NLRP6 and
NLRP12 have also been implicated in the recognition and de-
fense toward several bacteria, and the functions of other NLRs
remain poorly understood currently (Jin and Flavell, 2010; Lam-
kanfi and Dixit, 2012; Schroder and Tschopp, 2010; Vladimer
et al., 2012). Apart from these microbial stimuli, both TLRs and
NLRs have been demonstrated to sense a variety of DAMPs
derived from stress responses or tissue damage, which will be
discussed in detail below in the context of obesity-associated
metabolic disturbance. Other innate pattern recognition recep-
tors (PRRs) include RIG-I-like receptors (RLRs), AIM2-like recep-
tors (ALRs), and C-type lectin receptors (CLRs) (Takeuchi and
Akira, 2010). The cooperation between these compartmentalized
surveillance systems allows organisms to sense and respond to a
wide variety of infectious organisms and host-derived insults.
However, in the context of overnutrition, a recent acquired hu-
man trait, this elegant evolutionarily conserved defense system
boomerangs to the host by initiating immune responses toward
homeostatic perturbations associated with obesity. In this re-
view,weexamine the role of innate immune receptors in thepath-
ogenesis of the most prevalent obesity-associated diseases.
Activation of Innate Immune Receptors in Metabolic
Diseases
Multiple innate immune receptors including TLR2, TLR4,
TLR5, TLR9, NOD1/2, and NLRP3 have been implicated in theCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 873
Figure 1. Activation of Innate Immune
Receptor Signaling in Obesity-Associated
Metabolic Stress
During the development of metabolic diseases,
TLRs and NLRs can be activated by a variety of
dietary factors and endogenous damage-associ-
ated signals (DAMPs) as well as bacterial PAMPs
derived from intestinal microbiota. Free fatty acids
such as palmitate have been shown to activate
TLR2, TLR4, and NLRP3; ceramides and modified
low-density lipoprotein (LDL) can activate TLR4
andNLRP3.HMGB1and fetuinAhavebeenshown
to mediate TLR4 activation; high levels of glucose,
amyloid deposits in the diabetic islets, and crystals
of cholesterol and calcium in the atherosclerotic
plaque can activate the NLRP3 inflammasome
(green arrows). In addition, TLR4 can sense the
circulating LPS derived from gram-negative
commensal bacteria in the intestine, whereas
TLR9 and NOD1 have been shown to sense bac-
terial DNA and peptidoglycan (PGN) derived from
gut microbiota, respectively (blue arrows). Ligand
bindingof TLRsandNODs triggers theactivation of
IKKb and JNKs, leading to the expression of
proinflammatory cytokines including proIL-1b and
proIL-18. Ligand sensing by NLRP3 leads to
the assembly of a large multiprotein complex
named inflammasome that governscaspase-1activation andsubsequentmaturation andsecretion of IL-1band IL-18.On theother hand, innate immune receptors
are important regulators of the intestinal microbial communities, which have extensivemetabolic interactionswith themammalian host. Disruption of TLR2, TLR5,
NOD1/2, andNLRP3/NLRP6 inflammasomes has been associatedwith alteration in gutmicrobiota composition, themetabolic consequences of which have been
characterized in mice lacking TLR2, TLR5, and inflammasomes (red arrows).
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sponses in various tissues and thereby contributing to the devel-
opment of metabolic diseases. Ligand binding of TLRs and
NODs triggers a signaling cascade leading to the activation of
IKKb and MAPKs (such as p38, JNKs, and ERK1/2) and produc-
tion of inflammatory cytokines and/or type I interferons (Figure 1).
On the other hand, ligand sensing by NLRP3 leads to the assem-
bly of a large multiprotein complex named inflammasome that
governs caspase-1 activation and subsequent maturation and
secretion of the proinflammatory cytokines IL-1b and IL-18
(Figure 1). It is important to note that multiple TLRs, NODs, cyto-
kine signaling pathways and overnutrition-induced ER stress
converge onto the activation of major inflammatory kinases
JNK and IKKb, which directly interferes with insulin signal trans-
duction and also upregulates the expression of inflammatory
mediators (Gregor and Hotamisligil, 2011; Tanti et al., 2012).
Proinflammatory cytokines and chemokines further act in auto-
crine or paracrine manners to activate JNK and IKKb, and
mediate the recruitment and activation of multiple immune cell
types, establishing a feedforward amplification loop of inflamma-
tion within key metabolic tissues (Gregor and Hotamisligil, 2011;
Tanti et al., 2012).
A variety of PAMPs and DAMPs derived from intestinal mi-
crobiota and dietary factors have been proposed to activate
TLRs and NLRs during the development of metabolic diseases
(Figure 1, green and blue arrows). First, excessive nutrients or
their derivatives can be directly sensed by innate pathogen
receptors. Saturated long-chain fatty acids such as palmitate
have been shown to activate TLR2, TLR4, and NLRP3 (Davis
et al., 2008; Ko¨nner and Bru¨ning, 2011; Wen et al., 2011); ce-
ramides and modified low-density lipoprotein (LDL) can acti-
vate TLR4 and NLRP3 (den Dekker et al., 2010; Fischer
et al., 2007; Holland et al., 2011; Jiang et al., 2012; Vandan-874 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.magsar et al., 2011); and high levels of glucose and choles-
terol crystals can activate the NLRP3 inflammasome (Duewell
et al., 2010; Zhou et al., 2010). Second, innate immune recep-
tors can be triggered by the production of endogenous
damage-associated signals during the development of meta-
bolic diseases. For example, High Mobility Group Box 1
(HMGB1) and fetuin A are elevated in diet-induced obesity
and have been shown to mediate TLR4 activation (Li et al.,
2011; Pal et al., 2012), whereas amyloid deposits in the dia-
betic islets and calcium crystals in the atherosclerotic plaque
can activate the NLRP3 inflammasome (Masters et al., 2010;
Usui et al., 2012). Other endogenous ligands of TLR4 and
NLRP3 including heat shock proteins (HSP60/70), hyaluronan,
and uric acid are also increased in obese/diabetic subjects,
and therefore might contribute to TLR/NLR-mediated inflam-
mation in response to metabolic stress (De Nardo and Latz,
2011; Ko¨nner and Bru¨ning, 2011). Third, the development of
obesity, NAFLD, and diabetes is associated with alteration in
the gut microbiota (Nicholson et al., 2012). The TLR4 ligand
LPS derived from gram-negative commensal bacteria in the
intestine is moderately elevated in the circulation of obese
and T2DM subjects (Harte et al., 2012; Ko¨nner and Bru¨ning,
2011; Pussinen et al., 2011). This is possibly due to the alter-
ations in the composition of gut microbiota with overexpansion
of endotoxin-producing bacteria, increased gut permeability,
and enhanced translocation of live bacteria through intestinal
mucosa to blood and mesenteric adipose tissue (Amar et al.,
2011; Cani et al., 2007). In addition to TLR4, TLR9 and
NOD1 have been shown to sense bacterial DNA and PGN
derived from gut microbiota, respectively (Clarke et al., 2010;
Miura et al., 2010).
It is important to highlight that the innate pathogen-sensing
system has emerged as an important regulator of the intestinal
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tions with the mammalian host. Mice deficient in TLR2, TLR5,
NOD1/2, and NLRP3/NLRP6 inflammasomes have been shown
to develop altered gut microbiota composition (Figure 1, red
arrows) (Biswas and Kobayashi, 2013; Caricilli et al., 2011; Elinav
et al., 2011; Vijay-Kumar et al., 2010). The metabolic conse-
quences of dysbiosis have been characterized in some of these
knockout strains while others await further investigation (see
below).
Metabolic Syndrome and Type 2 Diabetes
Obesity is closely associated with multiple metabolic abnormal-
ities including insulin resistance, hyperglycemia, dyslipidemia,
hepatic steatosis, and hypertension, which are collectively
defined as metabolic syndrome. The development of metabolic
syndrome dramatically increases the risk for T2DM, which
affects more than 300 million people worldwide (World Health
Organization, 2013).
Regarding obesity-associated metabolic inflammation, it was
originally observed that the levels of proinflammatory cytokines
and acute phase response proteins such as TNF-a, IL-6, and C
reactive protein (CRP) are increased in the circulation and adi-
pose tissue of obese or diabetic subjects. Subsequent studies
using genetic mouse models have causally linked TNF-a, JNK,
and IKKb with the development of obesity and insulin resistance
(Gregor and Hotamisligil, 2011). Activated macrophages in
adipose tissue are proposed to be a major source of proinflam-
matory cytokines. Obesity-induced adipose inflammation is
featured by an increased number of infiltrating adipose tissue
macrophages (ATMs) and favored polarization of ATMs toward
classically activated proinflammatory M1 macrophages other
than alternatively activated anti-inflammatory M2 macrophages.
ATMs are recruited by chemokines. Deletion of CCL2 or its re-
ceptor CCR2 attenuates adipose tissue inflammation and
ectopic lipid accumulation and improves insulin sensitivity
(Kanda et al., 2006; Weisberg et al., 2006). It is suggested that
ATMs control the release of lipid from adipose tissue. Inflamma-
tory cytokines from ATMs can increase lipolysis, resulting in
excessive lipid delivery to other tissues such as liver and muscle
and thereby promoting ectopic lipid accumulation and exacer-
bating insulin resistance (Samuel and Shulman, 2012). Aside
from macrophages, many other types of immune cells including
different subsets of T lymphocytes (Feuerer et al., 2009; Nishi-
mura et al., 2009; Winer et al., 2009), B cells (DeFuria et al.,
2013; Winer et al., 2011), mast cells (Liu et al., 2009), and eosin-
ophils (Wu et al., 2011) also infiltrate into adipose tissue during
the development of obesity and regulate tissue inflammation
and insulin resistance. In addition, activation of JNK and IKKb
in adipocytes not only leads to the production of adipokines
and cytokines but can also induce the phosphorylation of inhib-
itory serine sites of Insulin Receptor Substrate (IRS) 1/2, thereby
disrupting insulin signal transduction leading to insulin resis-
tance in a cell-autonomous manner (Gregor and Hotamisligil,
2011).
Apart from adipose tissue, nutrient overload also triggers a
chronic inflammatory response in other metabolic organs,
leading to the production of inflammatory cytokines and
recruitment of immune cells. Metabolic inflammation in liver
and skeletal muscles has been causally linked with ectopiclipid accumulation and peripheral insulin resistance (Figure 2).
Overnutrition can also induce a chronic low-grade inflamma-
tion within the hypothalamus, resulting in central leptin/insulin
resistance and disruption of the neuronal control of energy
homeostasis (Figure 2) (Gregor and Hotamisligil, 2011). High-
fat diet (HFD) and central administration of glucose or fatty
acids have been shown to activate hypothalamic IKKb/NF-kB
signaling, which promotes food intake and nutrient storage
(Zhang et al., 2008). Furthermore, deletion of JNK1 in the cen-
tral nervous system has been shown to increase energy expen-
diture and protect against obesity, possibly through the action
of hypothalamic-pituitary-thyroid axis (Belgardt et al., 2010;
Sabio et al., 2010). Besides these major insulin target tissues,
hyperglycemia and elevated free fatty acids also induce islet
inflammation and result in increased apoptosis and impaired
insulin secretion of b cells, which is critical for the progression
from insulin resistance to T2DM (Figure 2) (Donath and Shoe-
lson, 2011).
Emerging evidence has revealed that multiple TLRs and NLRs
act upstream of JNK and IKKb by sensing metabolic distur-
bances or microbiota-derived PAMPs during obesity. The
expression of TLR2 and TLR4 is increased in muscle and adi-
pose tissue of obese/diabetic subjects and in circulating mono-
cytes of T2DM patients and correlates with the severity of insu-
lin resistance (Donath and Shoelson, 2011; Ko¨nner and Bru¨ning,
2011). A number of studies using different genetic models
(TLR4 knockout, C3H/HeJ, and C57BL/10ScN) have consis-
tently demonstrated that loss of TLR4 function reduces inflam-
mation and insulin resistance in the adipose tissue (Orr et al.,
2012; Poggi et al., 2007; Saberi et al., 2009; Shi et al., 2006;
Suganami et al., 2007; Tsukumo et al., 2007), which is mainly
attributable to loss of TLR4 function in the hematopoietic
compartment (Orr et al., 2012; Saberi et al., 2009). Moreover,
functional deficiency of TLR4 can reduce HFD-induced hepatic
steatosis and inflammation leading to improved hepatic insulin
sensitivity (Orr et al., 2012; Poggi et al., 2007; Shi et al., 2006;
Tsukumo et al., 2007). In addition, TLR4 inactivation has been
shown to attenuate lipid-induced insulin resistance in skeletal
muscle (Holland et al., 2011; Radin et al., 2008; Tsukumo
et al., 2007). Mice lacking CD14, an accessory protein that facil-
itates ligand binding of TLR4, were also found to be resistant to
HFD-induced obesity, adiposity, hepatic steatosis, glucose
intolerance, and hypertention, further supporting the involve-
ment of CD14-mediated TLR4 signaling in metabolic inflamma-
tion and insulin resistance (Roncon-Albuquerque et al., 2008).
TLR4 is also expressed in multiple cell types within the brain
(Hanisch et al., 2008). CNS-specific TLR4 blockade and
MyD88 deletion reduce fatty acid-induced leptin resistance
and diet-induced obesity (Kleinridders et al., 2009; Milanski
et al., 2009). TLR4 and accessary LPS-binding molecules MD-
2 and CD14 are also expressed in islet b cells (Vives-Pi et al.,
2003). TLR4 and MyD88 deficiency has been shown to protect
against palmitate-induced b cell dysfunction and to prevent the
recruitment of inflammatory monocytes into islets (Eguchi et al.,
2012).
Similar to TLR4, TLR2 has also been shown to mediate free
fatty acid-induced proinflammatory response in cultured adipo-
cytes, macrophages, and myotubes (Ko¨nner and Bru¨ning, 2011;
Nguyen et al., 2007; Senn, 2006). Ablating TLR2 signaling in vivoCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 875
Figure 2. The Role of Innate Immune
Receptors and Metabolic Inflammation in
Multiple Tissues
During the pathogenesis of obesity-associated
metabolic diseases, activation of multiple
TLRs, NODs, cytokine signaling pathways con-
verges onto the activation of key inflammatory
kinases JNK and IKKb, which directly interferes
with insulin signal transduction and also
upregulates the expression of inflammatory me-
diators. Proinflammatory cytokines and chemo-
kines further mediate the recruitment and
activation of multiple immune cell types, estab-
lishing a feedforward amplification loop of
inflammation within key metabolic tissues. This
metabolic inflammation dysregulates adipose
lipolysis and enhances hepatic steatosis; pro-
motes peripheral insulin resistance in liver,
muscle, and adipose tissue; drives central leptin/
insulin resistance in the hypothalamus; impairs
insulin secretion from b cells in pancreatic islets;
and triggers the initiation and progression of
atherosclerosis in blood vessels. In addition,
metabolic inflammation is associated with
increased gut permeability, while innate immune
receptors regulate the composition of the intes-
tinal microbiota, which in turn affects these
various metabolic processes. The combinatory effects in all these aspects contribute to the development of obesity-associated diseases such as metabolic
syndrome, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and cardiovascular disease.
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liver and adipose tissue (Ehses et al., 2010; Himes and Smith,
2010; Kuo et al., 2011) and generally improves peripheral insulin
sensitivity (Caricilli et al., 2008; Ehses et al., 2010; Himes and
Smith, 2010; Kuo et al., 2011). TLR2 is also expressed in
b cells, and TLR2 knockout mice are protected from impaired
insulin secretion and islet inflammation on HFD (Ehses et al.,
2010).
PGN-induced NOD1 activation has been shown to promote
proinflammatory response and insulin resistance as well as to
suppress differentiation in cultured adipocytes (Purohit et al.,
2012; Zhao et al., 2011). Acute administration of NOD1 agonist
triggers inflammation and insulin resistance in liver and adipose
tissue in vivo, and mice lacking NOD1 are protected from HFD-
induced adiposity and glucose intolerance (Amar et al., 2011;
Schertzer et al., 2011). In comparison, NOD2 activation seems
to mainly affect inflammation and insulin sensitivity in skeletal
muscle in vitro and in vivo (Schertzer et al., 2011; Tamrakar
et al., 2010).
The inflammasome effector cytokines IL-1b and IL-18 are
elevated in the circulation of individuals with obesity or T2DM
and correlated with the disease severity (Fe`ve and Bastard,
2009; Trøseid et al., 2010). Polymorphism in the genes encoding
IL-1 receptor antagonist and IL18 have been associated with
increased risk of metabolic syndrome (Presta et al., 2009;
Strandberg et al., 2006). IL-1b deficiency protects mice from
HFD-induced insulin resistance (Stienstra et al., 2010; Wen
et al., 2011), and treatment with IL-1 receptor antagonist reduces
hyperglycemia in obese/diabetic rodents and improves glycemic
control T2DM patients (Donath and Shoelson, 2011; Ehses et al.,
2009). The expression of NLRP3 and caspase-1 is increased in
adipose tissue of obese mice and humans, and reduction of
NLRP3, ASC, and IL-1b expression in adipose tissue correlates
with improvement of insulin sensitivity (Stienstra et al., 2010;876 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.Vandanmagsar et al., 2011). Mice lacking caspase-1 or NLRP3
have been shown to develop reduced adiposity and hepatic
steatosis with attenuated adipose inflammation, and to exhibit
improved insulin sensitivity upon HFD (Vandanmagsar et al.,
2011; Wen et al., 2011). Activation of the NLRP3 inflammasome
during obesity might be mediated by ceramides and long-chain
saturated fatty acids such as palmitate (Vandanmagsar et al.,
2011; Wen et al., 2011).
Inflammasomes also seem to play an important role in the
progression from insulin resistance to T2DM through the regu-
lation of b cells. IL-1b can be produced from islet-infiltrating
macrophages and b cells, and is upregulated in the islets of
patients and animal models with T2DM (Donath and Shoelson,
2011). IL-1b has been proposed to affect insulin production by
impairing the survival and the secretory function of pancreatic b
cells. In agreement with this notion, inactivation of IL-1 signaling
ameliorates glucose and palmitate-induced islet inflammation,
leading to improved glycemic control (Donath and Shoelson,
2011; Ehses et al., 2009). Activation of the NLRP3 inflam-
masome by elevated glucose level and amyloid deposits in
the islet has been suggested to induce IL-1b production during
the development of T2DM (Masters et al., 2010; Zhou et al.,
2010).
Furthermore, inflammasome might also be involved in meta-
bolic inflammation in the hypothalamus, as both IL-1b and IL18
have been implicated in central control of energy homeostasis.
Loss of IL-1 signaling seems to predispose mice to weight gain
(Osborn et al., 2008), whereas deficiency of IL-18 in mice leads
to hyperphagia, obesity, and insulin resistance (Netea et al.,
2006). Yet the exact role of upstream inflammasome pathway
in hypothalamus inflammation and central control of energy
homeostasis awaits further investigation.
Interestingly, in addition to dietary and environmental fac-
tors, TLRs and NLRs have recently been shown to be critical
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dence has suggested that the microbiota exerts a profound
impact on host metabolism through multiple mechanisms
such as promoting nutrient adsorption and energy storage,
modulating gut hormone expression, and inducing metabolic
endotoxemia and inflammation (Greiner and Ba¨ckhed, 2011;
Nicholson et al., 2012). The development of obesity (Turn-
baugh et al., 2009; Turnbaugh et al., 2006) and diabetes (Furet
et al., 2010; Larsen et al., 2010) has been associated with
alterations in the gut microbiota. A number of recent reports
have linked the regulation of the gut microbiome by innate
immune receptors to metabolic disease progression. For
instance, mice deficient in TLR5 (Vijay-Kumar et al., 2010),
TLR2 (Caricilli et al., 2011), and inflammasome adaptor protein
ASC (Henao-Mejia et al., 2012) have recently been shown to
be predisposed to obesity, steatosis, and insulin resistance
as a consequence of intestinal dysbiosis. These metabolic
phenotypes can be conferred to wild-type mice through
microbiota transmission and reversed by antibiotics. Taken
together, these studies reflect an emerging theme in which
the combination of specific environmental conditions and
genetic deletion of innate immune receptors determines the
outcome of multiple metabolic parameters via modulation of
gut microbiota.
In general, innate immune receptor-mediated metabolic
inflammation promotes peripheral insulin resistance in liver,
muscle, and adipose tissue; disrupts central control of energy
homeostasis in the hypothalamus; and impairs insulin secretion
in pancreatic islets. In addition, innate immune receptors regu-
late the composition of the intestinal microbiota, which in turn
affects various metabolic processes. The net effect of all these
aspects contributes to the development of metabolic syndrome
and T2DM (Figure 2).
Innate Immune Receptors as Determinants of NAFLD
Progression
NAFLD is the leading cause of chronic liver disease in Western
societies, with a prevalence of 30% in the general population
and up to 75%–100% in obese individuals. NAFLD is consid-
ered the hepatic manifestation of metabolic syndrome, and it
is expected that in 2030 the prevalence of NAFLD will reach
50% in the United States (Samuel and Shulman, 2012). While
most patients with steatosis remain asymptomatic, 20% prog-
ress to develop chronic hepatic inflammation (nonalcoholic
steatohepatitis, NASH), which in turn can lead to cirrhosis and
hepatocarcinoma (Serfaty and Lemoine, 2008). Despite its
high prevalence and the severe deleterious consequences of
inflammatory processes that accompany hepatic lipid accumu-
lation, factors leading to progression from NAFLD to NASH
remain poorly understood, and no treatment has proven
effective.
A combination of hepatic insults is proposed to drive NAFLD/
NASH pathogenesis. Hepatic steatosis predisposes the liver to
additional proinflammatory insults, which in turn promote infiltra-
tion of the hepatic parenchima by immune cells leading to dis-
ease progression. Thus, in the context of hepatic steatosis, the
parallel action of increased generation of reactive oxygen spe-
cies (ROS), augmented lipid peroxidation, and intestinal-derived
factors is required for the development of steatohepatitis (Sanyalet al., 2001). As each of these hepatic insults are known to acti-
vate a variety of innate immune pathways, a growing body of
research now functionally links the innate immune system to
NAFLD progression.
TLRs are widely expressed in multiple hepatic cells. In partic-
ular, Kupffer cells express high levels of TLR2, TLR4, and TLR9
(Miura et al., 2010; Rivera et al., 2007). Several lines of evidence
in TLR-deficient mice indicate that signaling through TLR4 and
TLR9 promotes the progression of NAFLD. Multiple groups
have demonstrated that activation of TLR4 signaling has a dele-
terious impact in different mousemodels of NAFLD (Rivera et al.,
2007). In concordance, serum levels of LPS are significantly
increased in patients with NAFLD, and antibiotic treatment atten-
uates steatosis in these individuals (Miele et al., 2009). Likewise,
it was demonstrated that while wild-typemice fed a choline-defi-
cient amino acid-defined diet develop severe steatohepatitis
and insulin resistance, Tlr9/ mice showed significant lower
levels of steatohepatitis; moreover, they had decreased insulin
resistance and signs of a fibrogenic response (Miura et al.,
2010). Thus, intrahepatic activation of TLR signaling by endoge-
nous and pathogen-derived ligands plays a critical role in the
development of NASH.
Various cell types in the liver express inflammasome compo-
nents. Kupffer cells and sinusoidal endothelial cells express
high levels of NLRP1, NLRP3, and AIM2, and hepatocytes upre-
gulate NLRP3 expression in an LPS-dependent manner (Boaru
et al., 2012). In parallel, inflammasomes play a critical role in
the regulation of the composition of the intestinal microbiota,
and their absence leads to the expansion of aberrant intestinal
microbial communities, which are characterized by its capacity
to promote colonic inflammation (Elinav et al., 2011). Since the
intestine and the liver are intimately and functionally linked by
the portal vein, recent evidence indicates that inflammasomes
have liver-intrinsic and -extrinsic roles during the development
of NAFLD.
We recently reported that the aberrant microbiota in inflam-
masome-deficient mice carry profound effects on NAFLD pro-
gression (Henao-Mejia et al., 2012). In different mouse models
of NASH we demonstrated that mice carrying the inflamma-
some-deficient associated procolitogenic flora develop more
severe NASH, which is fully transferable to wild-type mice
upon prolonged cohousing. The enhanced liver inflammation
is induced by increased levels of TLR4 and TLR9 agonists
in the portal circulation as a consequence of the expansion
of specific bacterial communities that are in close proximity
to the epithelial barrier. As a result, activation of TLR signaling
pathways leads to enhanced secretion of TNF-a and NASH
progression. In concordance with these findings in mouse
models, recent reports indicate that patients with inflamma-
tory bowel disease have significantly greater incidence of
NAFLD; moreover, this incidence was reduced among pa-
tients who received anti-TNF-a therapy (Sourianarayanane
et al., 2012).
Interestingly, Csak et al. showed a potential involvement of the
NLRP3 inflammasome in the development and progression of
NASH (Csak et al., 2011). Upon induction of NAFLD/NASH,
multiple inflammasome components were upregulated in the
liver; moreover, inflammasome activation was detected in
isolated hepatocytes. Mechanistically, palmitate was found toCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 877
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secretion.
In conclusion, in the context of inflammasome deficiency
and specific environmental settings, the expansion of procolito-
genic bacterial communities has a dominant-negative role in
the progression of NAFLD. On the other hand, intrahepatic
activation of inflammasomes during NAFLD suggests that their
activation in the absence of dysbiosis might have an important
role in the pathogenesis of this disease and warrants further
investigation.
Atherosclerosis
Cardiovascular disease (CVD) is the leading cause of mortality
worldwide, accounting for 16.7 million deaths each year, mainly
from myocardial infarction and strokes (Dahlo¨f, 2010). Epidemi-
ologic studies suggest CVD is increasingly prevalent and pre-
dicted to cause approximately 25 million deaths by 2020 (Dah-
lo¨f, 2010; Hansson and Hermansson, 2011). The most common
underlying cause of CVD is atherosclerosis, which is a chronic
inflammatory disease of blood vessels associated with lipid
accumulation and plaque formation in large and mid-sized ar-
teries. Atherosclerosis is promoted by obesity-associated
hyperlipidemia and inflammation, and accounts for 70%
morbidity of T2DM patients (De Nardo and Latz, 2011). Both
the innate and the adaptive immune system have been demon-
strated to play a crucial role in the pathogenesis of atheroscle-
rosis, and genetic deletion of multiple costimulatory factors and
proinflammatory cytokines has been shown to reduce disease
severity in mouse models (Hansson and Hermansson, 2011). At
the initiation of atherosclerosis, subendothelial retention of
circulating LDL particles predisposes the trapped lipids to
oxidative modification by oxygen radicals and enzymatic at-
tacks. Modified LDLs then activate innate immune receptors
(see below) and thereby trigger the inflammatory cascades
that induce the expression of a panel of proatherogenic factors
such as inflammatory cytokines, chemokines, proteinases, and
costimulatory molecules. The production of adhesion mole-
cules and chemokines from activated endothelial cells and
macrophages attract monocytes, dendritic cells (DCs), and
T cells into the intima. Differentiation of monocytes to macro-
phages and cholesterol accumulation eventually transform
these macrophages into foam cells. Stimulation of dendritic
cells switches on the adaptive immune response involving mul-
tiple T cell subsets as well as B cells and NKT cells. Neutrophils
and mast cells are also recruited to the atherosclerotic lesions,
which in combination with other innate as well as adaptive im-
mune cells produce proatherogenic mediators, contributing to
lesion growth and disease progression (Hansson and Her-
mansson, 2011).
Activation of innate immune receptors triggers the inflamma-
tory responses that drive both the initiation and progression of
atherosclerosis. A broad range of PRRs are expressed in mul-
tiple cell types present in arterial lesions, including endothelial
cells and recruited monocytes/macrophages and dendritic
cells. In the hypercholesterolemic apolipoprotein E(ApoE)-defi-
cient mouse model, lack of MyD88 suppresses atherosclerosis
development (Bjo¨rkbacka et al., 2004; Michelsen et al., 2004).
Genetic deficiency of TLR4 attenuates vascular inflammation
during HFD-induced obesity and reduces aortic plaque burden878 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.in ApoE knockout model (Kim et al., 2007; Michelsen et al.,
2004). Moreover, systemic or hematopoietic TLR4 deletion de-
creases atherosclerosis in LDL receptor (LDLR)-deficient mice
(Coenen et al., 2009; Ding et al., 2012). In addition to TLR4,
TLR2 deficiency reduces atherosclerosis severity in infected
ApoE+/ mice and ameliorates disease progression in
LDLR/ mice (Madan and Amar, 2008; Mullick et al., 2005).
Minimally oxidized LDL (mmLDL), oxidized LDL (oxLDL), fibro-
nectin, and heat shock proteins (HSPs) are putative TLR4
ligands in atherosclerotic lesions, whereas oxLDL and carbox-
yethylpyrrol are potential activators of TLR2 leading to
vascular response (Seimon et al., 2010; West et al., 2010).
Furthermore, bone marrow deficiency of TLR3, as well as
TLR-adaptors TRAM and TRIF, has also been shown to
protect against atherosclerosis in LDLR/ mice (Lundberg
et al., 2013).
Plasma concentrations of IL-1b and IL18 are both elevated in
atherosclerosis and associated with disease severity (De Nardo
and Latz, 2011). Deletion of NLRP3, ASC, or IL-1a/b in the
hematopoietic compartmentmarkedly reduces the development
of aortic lesion and circulating IL-18 level in LDLR/mice (Due-
well et al., 2010). Moreover, recent studies find caspase-1 defi-
ciency also reduces vascular inflammation and atherosclerosis
progression in ApoE/ model (Gage et al., 2012; Usui et al.,
2012), although one previous study did not observe any effect
of NLRP3 inflammasome deficiency in atherosclerosis severity
in the ApoE-deficientmice (Menu et al., 2011). The discrepancies
are most likely due to the different doses of cholesterol and
durations of the atherogenic diet used in these studies (De Nardo
and Latz, 2011). Uptake of oxLDL particles has been shown to
activate the NLRP3 inflammasome, whereas cholesterol crystals
and calcium crystals accumulated in the atherosclerotic plaque
can also trigger NLRP3 activation (Duewell et al., 2010; Usui
et al., 2012).
Concluding Remarks
Most metabolic and innate immune response pathways are
evolutionarily conserved throughout species and are funda-
mental to survival. As a result, metabolic regulation and im-
mune responses are intimately integrated and functionally
dependent. However, if a new variable is introduced to this
delicate interaction, it can lead to the conversion of what usu-
ally are beneficial physiological processes to pathological
events. In recent decades, the prevalence and incidence of
metabolic diseases associated with obesity has dramatically
increased worldwide. As newly acquired traits of the human
species, these pathological processes have exposed the
critical role of the immune system in the regulation of insulin
resistance, energy balance, atherosclerosis, and NAFLD pro-
gression. In particular, innate immune receptors have been
shown to be critical sensors of metabolic stress and key deter-
minants in the initiation of metabolic inflammation. However,
and despite intense research in the last lustrum, we still have
precarious knowledge on which are the endogenous and envi-
ronmental cues that drive inflammation in the context of nutri-
tional surplus, what is the sequence of events that lead to
chronic low-grade inflammation during obesity, or what is
exact contribution of different cell types of the immune system
to the progression of these multifactorial diseases. Moreover,
Cell Metabolism
Perspectivethe composition of the intestinal microflora and its regulation by
the innate immune system have emerged as critical determi-
nants of metabolic disease progression in recent years; never-
theless, the exact bacterial species involved in this processes
and the commensal-derived products that regulate whole-
body metabolism remain to be determined. Answering these
questions will potentially lead to improved therapeutic
approaches for these devastating diseases.ACKNOWLEDGMENTS
We thank Caroline Lieber for help with the submission of this manuscript. We
apologize to those whose work was not cited owing to space constraints.
J.H.-M. is supported by a Postdoctoral Fellowship from the Leukemia and
Lymphoma Society. R.A.F. is an Investigator of the Howard Hughes Medical
Institute.REFERENCES
Amar, J., Chabo, C., Waget, A., Klopp, P., Vachoux, C., Bermu´dez-Humara´n,
L.G., Smirnova, N., Berge´, M., Sulpice, T., Lahtinen, S., et al. (2011). Intestinal
mucosal adherence and translocation of commensal bacteria at the early
onset of type 2 diabetes: molecular mechanisms and probiotic treatment.
EMBO Mol. Med. 3, 559–572.
Belgardt, B.F., Mauer, J., Wunderlich, F.T., Ernst, M.B., Pal, M., Spohn, G.,
Bro¨nneke, H.S., Brodesser, S., Hampel, B., Schauss, A.C., and Bru¨ning,
J.C. (2010). Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling
coordinately regulates glucose metabolism. Proc. Natl. Acad. Sci. USA 107,
6028–6033.
Biswas, A., and Kobayashi, K.S. (2013). Regulation of intestinal microbiota by
the NLR protein family. Int. Immunol. 25, 207–214.
Bjo¨rkbacka, H., Kunjathoor, V.V., Moore, K.J., Koehn, S., Ordija, C.M., Lee,
M.A., Means, T., Halmen, K., Luster, A.D., Golenbock, D.T., and Freeman,
M.W. (2004). Reduced atherosclerosis in MyD88-null mice links elevated
serum cholesterol levels to activation of innate immunity signaling pathways.
Nat. Med. 10, 416–421.
Boaru, S.G., Borkham-Kamphorst, E., Tihaa, L., Haas, U., andWeiskirchen, R.
(2012). Expression analysis of inflammasomes in experimental models of in-
flammatory and fibrotic liver disease. J. Inflamm. (Lond.) 9, 49.
Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D.,
Neyrinck, A.M., Fava, F., Tuohy, K.M., Chabo, C., et al. (2007). Metabolic
endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–
1772.
Caricilli, A.M., Nascimento, P.H., Pauli, J.R., Tsukumo, D.M., Velloso, L.A.,
Carvalheira, J.B., and Saad, M.J. (2008). Inhibition of toll-like receptor 2
expression improves insulin sensitivity and signaling in muscle and white adi-
pose tissue of mice fed a high-fat diet. J. Endocrinol. 199, 399–406.
Caricilli, A.M., Picardi, P.K., de Abreu, L.L., Ueno, M., Prada, P.O., Ropelle,
E.R., Hirabara, S.M., Castoldi, A., Vieira, P., Camara, N.O., et al. (2011). Gut
microbiota is a key modulator of insulin resistance in TLR 2 knockout mice.
PLoS Biol. 9, e1001212.
Clarke, T.B., Davis, K.M., Lysenko, E.S., Zhou, A.Y., Yu, Y., and Weiser, J.N.
(2010). Recognition of peptidoglycan from the microbiota by Nod1 enhances
systemic innate immunity. Nat. Med. 16, 228–231.
Coenen, K.R., Gruen, M.L., Lee-Young, R.S., Puglisi, M.J., Wasserman, D.H.,
and Hasty, A.H. (2009). Impact of macrophage toll-like receptor 4 deficiency
on macrophage infiltration into adipose tissue and the artery wall in mice.
Diabetologia 52, 318–328.
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., and Szabo, G. (2011).
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that
release danger signals to stimulate immune cells. Hepatology 54, 133–144.
Dahlo¨f, B. (2010). Cardiovascular disease risk factors: epidemiology and risk
assessment. Am. J. Cardiol. 105(1, Suppl), 3A–9A.Davis, J.E., Gabler, N.K., Walker-Daniels, J., and Spurlock, M.E. (2008). Tlr-4
deficiency selectively protects against obesity induced by diets high in satu-
rated fat. Obesity (Silver Spring) 16, 1248–1255.
DeFuria, J., Belkina, A.C., Jagannathan-Bogdan, M., Snyder-Cappione, J.,
Carr, J.D., Nersesova, Y.R., Markham, D., Strissel, K.J., Watkins, A.A., Zhu,
M., et al. (2013). B cells promote inflammation in obesity and type 2 diabetes
through regulation of T-cell function and an inflammatory cytokine profile.
Proc. Natl. Acad. Sci. USA 110, 5133–5138.
De Nardo, D., and Latz, E. (2011). NLRP3 inflammasomes link inflammation
and metabolic disease. Trends Immunol. 32, 373–379.
den Dekker, W.K., Cheng, C., Pasterkamp, G., and Duckers, H.J. (2010). Toll
like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis
209, 314–320.
Ding, Y., Subramanian, S., Montes, V.N., Goodspeed, L., Wang, S., Han, C.,
Teresa, A.S., 3rd, Kim, J., O’Brien, K.D., and Chait, A. (2012). Toll-like receptor
4 deficiency decreases atherosclerosis but does not protect against inflamma-
tion in obese low-density lipoprotein receptor-deficient mice. Arterioscler.
Thromb. Vasc. Biol. 32, 1596–1604.
Donath, M.Y., and Shoelson, S.E. (2011). Type 2 diabetes as an inflammatory
disease. Nat. Rev. Immunol. 11, 98–107.
Duewell, P., Kono, H., Rayner, K.J., Sirois, C.M., Vladimer, G., Bauernfeind,
F.G., Abela, G.S., Franchi, L., Nun˜ez, G., Schnurr, M., et al. (2010). NLRP3 in-
flammasomes are required for atherogenesis and activated by cholesterol
crystals. Nature 464, 1357–1361.
Eguchi, K., Manabe, I., Oishi-Tanaka, Y., Ohsugi, M., Kono, N., Ogata, F., Yagi,
N., Ohto, U., Kimoto, M., Miyake, K., et al. (2012). Saturated fatty acid and TLR
signaling link b cell dysfunction and islet inflammation. Cell Metab. 15,
518–533.
Ehses, J.A., Lacraz, G., Giroix, M.H., Schmidlin, F., Coulaud, J., Kassis, N.,
Irminger, J.C., Kergoat, M., Portha, B., Homo-Delarche, F., and Donath,
M.Y. (2009). IL-1 antagonism reduces hyperglycemia and tissue inflam-
mation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. USA 106,
13998–14003.
Ehses, J.A., Meier, D.T., Wueest, S., Rytka, J., Boller, S., Wielinga, P.Y.,
Schraenen, A., Lemaire, K., Debray, S., Van Lommel, L., et al. (2010).
Toll-like receptor 2-deficient mice are protected from insulin resistance
and beta cell dysfunction induced by a high-fat diet. Diabetologia 53, 1795–
1806.
Elinav, E., Strowig, T., Kau, A.L., Henao-Mejia, J., Thaiss, C.A., Booth, C.J.,
Peaper, D.R., Bertin, J., Eisenbarth, S.C., Gordon, J.I., and Flavell, R.A.
(2011). NLRP6 inflammasome regulates colonic microbial ecology and risk
for colitis. Cell 145, 745–757.
Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J.,
Goldfine, A.B., Benoist, C., Shoelson, S., and Mathis, D. (2009). Lean, but
not obese, fat is enriched for a unique population of regulatory T cells that
affect metabolic parameters. Nat. Med. 15, 930–939.
Fe`ve, B., and Bastard, J.P. (2009). The role of interleukins in insulin resistance
and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5, 305–311.
Fischer, H., Ellstro¨m, P., Ekstro¨m, K., Gustafsson, L., Gustafsson, M., and
Svanborg, C. (2007). Ceramide as a TLR4 agonist; a putative signalling inter-
mediate between sphingolipid receptors for microbial ligands and TLR4.
Cell. Microbiol. 9, 1239–1251.
Furet, J.P., Kong, L.C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J.L., Mariat,
D., Corthier, G., Dore´, J., Henegar, C., et al. (2010). Differential adapta-
tion of human gut microbiota to bariatric surgery-induced weight loss:
links with metabolic and low-grade inflammation markers. Diabetes 59,
3049–3057.
Gage, J., Hasu, M., Thabet, M., and Whitman, S.C. (2012). Caspase-1 defi-
ciency decreases atherosclerosis in apolipoprotein E-null mice. Can. J.
Cardiol. 28, 222–229.
Gregor, M.F., and Hotamisligil, G.S. (2011). Inflammatory mechanisms in
obesity. Annu. Rev. Immunol. 29, 415–445.
Greiner, T., and Ba¨ckhed, F. (2011). Effects of the gut microbiota on obesity
and glucose homeostasis. Trends Endocrinol. Metab. 22, 117–123.Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 879
Cell Metabolism
PerspectiveHanisch, U.K., Johnson, T.V., and Kipnis, J. (2008). Toll-like receptors: roles in
neuroprotection? Trends Neurosci. 31, 176–182.
Hansson, G.K., and Hermansson, A. (2011). The immune system in atheroscle-
rosis. Nat. Immunol. 12, 204–212.
Harte, A.L., Varma, M.C., Tripathi, G., McGee, K.C., Al-Daghri, N.M., Al-Attas,
O.S., Sabico, S., O’Hare, J.P., Ceriello, A., Saravanan, P., et al. (2012). High fat
intake leads to acute postprandial exposure to circulating endotoxin in type 2
diabetic subjects. Diabetes Care 35, 375–382.
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W.Z., Strowig, T., Thaiss,
C.A., Kau, A.L., Eisenbarth, S.C., Jurczak, M.J., et al. (2012). Inflammasome-
mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482,
179–185.
Himes, R.W., and Smith, C.W. (2010). Tlr2 is critical for diet-induced metabolic
syndrome in a murine model. FASEB J. 24, 731–739.
Holland, W.L., Bikman, B.T., Wang, L.P., Yuguang, G., Sargent, K.M.,
Bulchand, S., Knotts, T.A., Shui, G., Clegg, D.J., Wenk, M.R., et al. (2011).
Lipid-induced insulin resistance mediated by the proinflammatory receptor
TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice.
J. Clin. Invest. 121, 1858–1870.
Jiang, Y., Wang, M., Huang, K., Zhang, Z., Shao, N., Zhang, Y., Wang, W., and
Wang, S. (2012). Oxidized low-density lipoprotein induces secretion of inter-
leukin-1b by macrophages via reactive oxygen species-dependent NLRP3 in-
flammasome activation. Biochem. Biophys. Res. Commun. 425, 121–126.
Jin, C., and Flavell, R.A. (2010). Molecular mechanism of NLRP3 inflamma-
some activation. J. Clin. Immunol. 30, 628–631.
Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa,
S., Miyachi, H., Maeda, S., Egashira, K., and Kasuga, M. (2006). MCP-1 con-
tributes to macrophage infiltration into adipose tissue, insulin resistance, and
hepatic steatosis in obesity. J. Clin. Invest. 116, 1494–1505.
Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in
innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373–384.
Kim, F., Pham, M., Luttrell, I., Bannerman, D.D., Tupper, J., Thaler, J., Hawn,
T.R., Raines, E.W., and Schwartz, M.W. (2007). Toll-like receptor-4 mediates
vascular inflammation and insulin resistance in diet-induced obesity. Circ.
Res. 100, 1589–1596.
Kleinridders, A., Schenten, D., Ko¨nner, A.C., Belgardt, B.F., Mauer, J.,
Okamura, T., Wunderlich, F.T., Medzhitov, R., and Bru¨ning, J.C. (2009).
MyD88 signaling in the CNS is required for development of fatty acid-induced
leptin resistance and diet-induced obesity. Cell Metab. 10, 249–259.
Ko¨nner, A.C., and Bru¨ning, J.C. (2011). Toll-like receptors: linking inflammation
to metabolism. Trends Endocrinol. Metab. 22, 16–23.
Kuo, L.H., Tsai, P.J., Jiang, M.J., Chuang, Y.L., Yu, L., Lai, K.T., and Tsai, Y.S.
(2011). Toll-like receptor 2 deficiency improves insulin sensitivity and hepatic
insulin signalling in the mouse. Diabetologia 54, 168–179.
Lamkanfi, M., and Dixit, V.M. (2012). Inflammasomes and their roles in health
and disease. Annu. Rev. Cell Dev. Biol. 28, 137–161.
Larsen, N., Vogensen, F.K., van den Berg, F.W., Nielsen, D.S., Andreasen,
A.S., Pedersen, B.K., Al-Soud,W.A., Sørensen, S.J., Hansen, L.H., and Jakob-
sen, M. (2010). Gut microbiota in human adults with type 2 diabetes differs
from non-diabetic adults. PLoS ONE 5, e9085.
Li, L., Chen, L., Hu, L., Liu, Y., Sun, H.Y., Tang, J., Hou, Y.J., Chang, Y.X., Tu,
Q.Q., Feng, G.S., et al. (2011). Nuclear factor high-mobility group box1 medi-
ating the activation of Toll-like receptor 4 signaling in hepatocytes in the early
stage of nonalcoholic fatty liver disease in mice. Hepatology 54, 1620–1630.
Liu, J., Divoux, A., Sun, J., Zhang, J., Cle´ment, K., Glickman, J.N., Sukhova,
G.K., Wolters, P.J., Du, J., Gorgun, C.Z., et al. (2009). Genetic deficiency
and pharmacological stabilization of mast cells reduce diet-induced obesity
and diabetes in mice. Nat. Med. 15, 940–945.
Lundberg, A.M., Ketelhuth, D.F., Johansson, M.E., Gerdes, N., Liu, S., Yama-
moto, M., Akira, S., and Hansson, G.K. (2013). Toll-like receptor 3 and 4 signal-
ling through the TRIF and TRAM adaptors in haematopoietic cells promotes
atherosclerosis. Cardiovasc. Res. http://dx.doi.org/10.1093/cvr/cvt033.880 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.Madan, M., and Amar, S. (2008). Toll-like receptor-2 mediates diet and/or
pathogen associated atherosclerosis: proteomic findings. PLoS ONE 3,
e3204. http://dx.doi.org/10.1371/journal.pone.0003204.
Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp,
F.A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010). Activation of
the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism
for enhanced IL-1b in type 2 diabetes. Nat. Immunol. 11, 897–904.
Menu, P., Pellegrin, M., Aubert, J.F., Bouzourene, K., Tardivel, A., Mazzolai, L.,
and Tschopp, J. (2011). Atherosclerosis in ApoE-deficient mice progresses
independently of the NLRP3 inflammasome. Cell Death Dis. 2, e137.
Michelsen, K.S., Wong, M.H., Shah, P.K., Zhang, W., Yano, J., Doherty, T.M.,
Akira, S., Rajavashisth, T.B., and Arditi, M. (2004). Lack of Toll-like receptor 4
or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque
phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA
101, 10679–10684.
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R.,
Masciana`, R., Forgione, A., Gabrieli, M.L., Perotti, G., et al. (2009). Increased
intestinal permeability and tight junction alterations in nonalcoholic fatty liver
disease. Hepatology 49, 1877–1887.
Milanski, M., Degasperi, G., Coope, A., Morari, J., Denis, R., Cintra, D.E., Tsu-
kumo, D.M., Anhe, G., Amaral, M.E., Takahashi, H.K., et al. (2009). Saturated
fatty acids produce an inflammatory response predominantly through the acti-
vation of TLR4 signaling in hypothalamus: implications for the pathogenesis of
obesity. J. Neurosci. 29, 359–370.
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olef-
sky, J.M., Brenner, D.A., and Seki, E. (2010). Toll-like receptor 9 promotes
steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology
139, 323–334.
Mullick, A.E., Tobias, P.S., and Curtiss, L.K. (2005). Modulation of atheroscle-
rosis in mice by Toll-like receptor 2. J. Clin. Invest. 115, 3149–3156.
Netea, M.G., Joosten, L.A., Lewis, E., Jensen, D.R., Voshol, P.J., Kullberg,
B.J., Tack, C.J., van Krieken, H., Kim, S.H., Stalenhoef, A.F., et al. (2006).
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin
resistance. Nat. Med. 12, 650–656.
Nguyen, M.T., Favelyukis, S., Nguyen, A.K., Reichart, D., Scott, P.A., Jenn, A.,
Liu-Bryan, R., Glass, C.K., Neels, J.G., and Olefsky, J.M. (2007). A subpopula-
tion of macrophages infiltrates hypertrophic adipose tissue and is activated by
free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways.
J. Biol. Chem. 282, 35279–35292.
Nicholson, J.K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., and
Pettersson, S. (2012). Host-gut microbiota metabolic interactions. Science
336, 1262–1267.
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M.,
Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009). CD8+ effector T cells
contribute to macrophage recruitment and adipose tissue inflammation in
obesity. Nat. Med. 15, 914–920.
Orr, J.S., Puglisi, M.J., Ellacott, K.L., Lumeng, C.N., Wasserman, D.H., and
Hasty, A.H. (2012). Toll-like receptor 4 deficiency promotes the alternative
activation of adipose tissue macrophages. Diabetes 61, 2718–2727.
Osborn, O., Gram, H., Zorrilla, E.P., Conti, B., and Bartfai, T. (2008). Insights
into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity
and insulin resistance. Swiss Med. Wkly. 138, 665–673.
Pal, D., Dasgupta, S., Kundu, R., Maitra, S., Das, G., Mukhopadhyay, S., Ray,
S., Majumdar, S.S., and Bhattacharya, S. (2012). Fetuin-A acts as an endoge-
nous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med.
http://dx.doi.org/10.1038/nm.2851.
Poggi, M., Bastelica, D., Gual, P., Iglesias, M.A., Gremeaux, T., Knauf, C., Peir-
etti, F., Verdier, M., Juhan-Vague, I., Tanti, J.F., et al. (2007). C3H/HeJ mice
carrying a toll-like receptor 4 mutation are protected against the development
of insulin resistance in white adipose tissue in response to a high-fat diet.
Diabetologia 50, 1267–1276.
Presta, I., Andreozzi, F., Succurro, E., Marini, M.A., Laratta, E., Lauro, R.,
Hribal, M.L., Perticone, F., and Sesti, G. (2009). IL-18 gene polymorphism
and metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 19, e5–e6.
Cell Metabolism
PerspectivePurohit, J., Hu, P., Burke, S.J., Collier, J.J., Chen, J., and Zhao, L. (2012). The
effects of NOD activation on adipocyte differentiation. Obesity (Silver Spring).
http://dx.doi.org/10.1038/oby.2012.155.
Pussinen, P.J., Havulinna, A.S., Lehto, M., Sundvall, J., and Salomaa, V.
(2011). Endotoxemia is associated with an increased risk of incident diabetes.
Diabetes Care 34, 392–397.
Radin, M.S., Sinha, S., Bhatt, B.A., Dedousis, N., and O’Doherty, R.M. (2008).
Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4
confers partial protection against lipid-induced insulin resistance in rodent
skeletal muscle. Diabetologia 51, 336–346.
Rivera, C.A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., and
Wallace, M. (2007). Toll-like receptor-4 signaling and Kupffer cells play pivotal
roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47,
571–579.
Roncon-Albuquerque, R., Jr., Moreira-Rodrigues, M., Faria, B., Ferreira, A.P.,
Cerqueira, C., Lourenc¸o, A.P., Pestana, M., von Hafe, P., and Leite-Moreira,
A.F. (2008). Attenuation of the cardiovascular and metabolic complications
of obesity in CD14 knockout mice. Life Sci. 83, 502–510.
Saberi, M., Woods, N.B., de Luca, C., Schenk, S., Lu, J.C., Bandyopadhyay,
G., Verma, I.M., and Olefsky, J.M. (2009). Hematopoietic cell-specific deletion
of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance
in high-fat-fed mice. Cell Metab. 10, 419–429.
Sabio, G., Cavanagh-Kyros, J., Barrett, T., Jung, D.Y., Ko, H.J., Ong, H.,Morel,
C., Mora, A., Reilly, J., Kim, J.K., and Davis, R.J. (2010). Role of the hypotha-
lamic-pituitary-thyroid axis in metabolic regulation by JNK1. Genes Dev. 24,
256–264.
Samuel, V.T., and Shulman, G.I. (2012). Mechanisms for insulin resistance:
common threads and missing links. Cell 148, 852–871.
Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J.,
Sterling, R.K., Luketic, V.A., Shiffman, M.L., and Clore, J.N. (2001). Nonalco-
holic steatohepatitis: association of insulin resistance and mitochondrial
abnormalities. Gastroenterology 120, 1183–1192.
Schertzer, J.D., Tamrakar, A.K., Magalha˜es, J.G., Pereira, S., Bilan, P.J.,
Fullerton, M.D., Liu, Z., Steinberg, G.R., Giacca, A., Philpott, D.J., and Klip,
A. (2011). NOD1 activators link innate immunity to insulin resistance. Diabetes
60, 2206–2215.
Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821–832.
Seimon, T.A., Nadolski, M.J., Liao, X., Magallon, J., Nguyen, M., Feric, N.T.,
Koschinsky, M.L., Harkewicz, R., Witztum, J.L., Tsimikas, S., et al. (2010).
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis
in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12,
467–482.
Senn, J.J. (2006). Toll-like receptor-2 is essential for the development of palmi-
tate-induced insulin resistance inmyotubes. J. Biol. Chem. 281, 26865–26875.
Serfaty, L., and Lemoine, M. (2008). Definition and natural history of metabolic
steatosis: clinical aspects of NAFLD, NASH and cirrhosis. DiabetesMetab. 34,
634–637.
Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. (2006).
TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin.
Invest. 116, 3015–3025.
Sourianarayanane, A., Garg, G., Smith, T.H., Butt, M.I., McCullough, A.J., and
Shen, B. (2012). Risk factors of non-alcoholic fatty liver disease in patients with
inflammatory bowel disease. J. Crohns Colitis.. http://dx.doi.org/10.1016/j.
crohns.2012.10.015.
Stienstra, R., Joosten, L.A., Koenen, T., van Tits, B., van Diepen, J.A., van den
Berg, S.A., Rensen, P.C., Voshol, P.J., Fantuzzi, G., Hijmans, A., et al. (2010).
The inflammasome-mediated caspase-1 activation controls adipocyte differ-
entiation and insulin sensitivity. Cell Metab. 12, 593–605.
Strandberg, L., Lorentzon, M., Hellqvist, A., Nilsson, S., Wallenius, V., Ohlsson,
C., and Jansson, J.O. (2006). Interleukin-1 system gene polymorphisms are
associated with fat mass in young men. J. Clin. Endocrinol. Metab. 91,
2749–2754.
Suganami, T., Mieda, T., Itoh, M., Shimoda, Y., Kamei, Y., and Ogawa, Y.
(2007). Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem. Biophys. Res.
Commun. 354, 45–49.
Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflam-
mation. Cell 140, 805–820.
Tamrakar, A.K., Schertzer, J.D., Chiu, T.T., Foley, K.P., Bilan, P.J., Philpott,
D.J., and Klip, A. (2010). NOD2 activation induces muscle cell-autonomous
innate immune responses and insulin resistance. Endocrinology 151, 5624–
5637.
Tanti, J.F., Ceppo, F., Jager, J., and Berthou, F. (2012). Implication of inflam-
matory signaling pathways in obesity-induced insulin resistance. Front Endo-
crinol (Lausanne) 3, 181.
Trøseid,M., Seljeflot, I., and Arnesen, H. (2010). The role of interleukin-18 in the
metabolic syndrome. Cardiovasc. Diabetol. 9, 11.
Tsukumo, D.M., Carvalho-Filho, M.A., Carvalheira, J.B., Prada, P.O., Hirabara,
S.M., Schenka, A.A., Arau´jo, E.P., Vassallo, J., Curi, R., Velloso, L.A., and
Saad, M.J. (2007). Loss-of-function mutation in Toll-like receptor 4 prevents
diet-induced obesity and insulin resistance. Diabetes 56, 1986–1998.
Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., and
Gordon, J.I. (2006). An obesity-associated gut microbiome with increased
capacity for energy harvest. Nature 444, 1027–1031.
Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley,
R.E., Sogin, M.L., Jones,W.J., Roe, B.A., Affourtit, J.P., et al. (2009). A core gut
microbiome in obese and lean twins. Nature 457, 480–484.
Usui, F., Shirasuna, K., Kimura, H., Tatsumi, K., Kawashima, A., Karasawa, T.,
Hida, S., Sagara, J., Taniguchi, S., and Takahashi, M. (2012). Critical role of
caspase-1 in vascular inflammation and development of atherosclerosis in
Western diet-fed apolipoprotein E-deficient mice. Biochem. Biophys. Res.
Commun. 425, 162–168.
Vandanmagsar, B., Youm, Y.H., Ravussin, A., Galgani, J.E., Stadler, K.,
Mynatt, R.L., Ravussin, E., Stephens, J.M., and Dixit, V.D. (2011). The
NLRP3 inflammasome instigates obesity-induced inflammation and insulin
resistance. Nat. Med. 17, 179–188.
Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., Cullender, T.C., Mwangi, S., Sri-
nivasan, S., Sitaraman, S.V., Knight, R., Ley, R.E., and Gewirtz, A.T. (2010).
Metabolic syndrome and altered gutmicrobiota inmice lacking Toll-like recep-
tor 5. Science 328, 228–231.
Vives-Pi, M., Somoza, N., Ferna´ndez-Alvarez, J., Vargas, F., Caro, P., Alba, A.,
Gomis, R., Labeta, M.O., and Pujol-Borrell, R. (2003). Evidence of expression
of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associ-
ated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells.
Clin. Exp. Immunol. 133, 208–218.
Vladimer, G.I., Weng, D., Paquette, S.W., Vanaja, S.K., Rathinam, V.A., Aune,
M.H., Conlon, J.E., Burbage, J.J., Proulx, M.K., Liu, Q., et al. (2012). The
NLRP12 inflammasome recognizes Yersinia pestis. Immunity 37, 96–107.
Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K.,
Charo, I., Leibel, R.L., and Ferrante, A.W., Jr. (2006). CCR2 modulates inflam-
matory and metabolic effects of high-fat feeding. J. Clin. Invest. 116, 115–124.
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M.T., Brickey, W.J., and
Ting, J.P. (2011). Fatty acid-induced NLRP3-ASC inflammasome activation in-
terferes with insulin signaling. Nat. Immunol. 12, 408–415.
West, X.Z., Malinin, N.L., Merkulova, A.A., Tischenko, M., Kerr, B.A., Borden,
E.C., Podrez, E.A., Salomon, R.G., and Byzova, T.V. (2010). Oxidative stress
induces angiogenesis by activating TLR2 with novel endogenous ligands.
Nature 467, 972–976.
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R.,
Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009). Normalization of obesity-
associated insulin resistance through immunotherapy. Nat. Med. 15, 921–929.
Winer, D.A., Winer, S., Shen, L., Wadia, P.P., Yantha, J., Paltser, G., Tsui, H.,
Wu, P., Davidson, M.G., Alonso, M.N., et al. (2011). B cells promote insulin
resistance through modulation of T cells and production of pathogenic IgG
antibodies. Nat. Med. 17, 610–617.
World Health Organization. (2013). Fact sheets. http://www.who.int/
mediacentre/factsheets/.Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 881
Cell Metabolism
PerspectiveWu, D., Molofsky, A.B., Liang, H.E., Ricardo-Gonzalez, R.R., Jouihan, H.A.,
Bando, J.K., Chawla, A., and Locksley, R.M. (2011). Eosinophils sustain adi-
pose alternatively activated macrophages associated with glucose homeosta-
sis. Science 332, 243–247.
Zhang, X., Zhang, G., Zhang, H., Karin, M., Bai, H., and Cai, D. (2008).
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy
imbalance and obesity. Cell 135, 61–73.882 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.Zhao, L., Hu, P., Zhou, Y., Purohit, J., and Hwang, D. (2011). NOD1 activation
induces proinflammatory gene expression and insulin resistance in 3T3-L1
adipocytes. Am. J. Physiol. Endocrinol. Metab. 301, E587–E598.Zhou, R., Tardivel, A., Thorens, B., Choi, I., and Tschopp, J. (2010). Thiore-
doxin-interacting protein links oxidative stress to inflammasome activation.
Nat. Immunol. 11, 136–140.
